



2024/10/22

產業類別	生技	
投資建議	中立	
收盤價	NT\$ 45.90	目標價
		NT\$

本次報告：法說會

交易資料

潛在報酬率 (%)	--
52 週還原收盤價區間 (NT\$)	41.60-62.50
市值 (NT\$百萬元)	7660
市值 (US\$百萬美元)	239
流通在外股數 (百萬股)	167.00
董監持股 (%)	9.66
外資持股 (%)	22.60
投信持股 (%)	0.04
融資使用率 (%)	--

財務資料

	2023
股東權益 (NT\$百萬元)	6,458
ROA (%)	3.17
ROE (%)	6.65
淨負債比率 (%)	50.23

公司簡介

業為一從事醫療設備經銷及全方位醫管服務之專業公司，營運據點涵蓋台灣(台北營運總部、台中及高雄)、中國(廣州、北京、瀋陽)及印尼雅加達三地，1H24 設備銷售、醫管服務及新事業體(藥品供應、保健食品銷售等)營收佔比各約 24%、43%及 33%。

主要客戶：

主要競爭對手：

陳奕均 fion.chen@sinopac.com

承業醫 (4164 TT)

再觀察


永豐觀點

營運谷底已過，惟輻照工廠訂單放量及毛利率是否如期回升還需再觀察。

投資評價與建議


投資建議：雖營運谷底已過，惟考量輻照工廠訂單放量及毛利率是否如期回升還需再觀察，加上以 2025 年預估稅後 EPS，目前本益比 15X，評價也合理，調降評等至中立。

近八季營收及 YoY 趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Oct. 2024

近八季營業利益及毛利率趨勢圖



資料來源：CMoney；永豐投顧研究處整理，Oct. 2024

營運現況與分析

公司簡介：承業為一從事醫療設備經銷(放射腫瘤影像醫學、神經醫學外科/手術及眼科)及全方位醫管服務(營運諮詢、設備合作及個別科室託管服務)之專業公司。營運據點涵蓋台灣(台北營運總部、台中及高雄)、中國(廣州、北京、瀋陽)及印尼雅加達三地。1H24 設備銷售、醫管服務及新事業體(藥品供應、保健食品銷售等)營收佔比各約 24%、43%及 33%。

毛利率明顯滑落，1H24 營運表現不佳，2H24 進入設備認列高峰，營收表現將優於 1H24：承業 1H24 營收 16.2 億元(-4.2%YoY)，毛利率 20.77%，較往年均值約 30%低，主因設備銷售廠商價格調漲，惟此部分承業已在明年的產品出貨上反應之，預期明年設備銷售端毛利率將可回升，另醫管服務因醫院服務量能受限、勞力吃緊，故也影響毛利率表現，稅後淨利 0.3 億元(-82.6%YoY)，稅後 EPS 0.18 元，表現不如預期。3Q 營收 9.64 億元(+0.6%QoQ、+30.7%YoY)，由於 4Q 通常為年底設備入帳高峰，預估 4Q 營收將再增至 9.95 億元(+3.2%QoQ、-31.5%YoY)，營收較去年同期滑落幅度較大，主因去年 4Q 認列出貨予國防醫學院高單價機種 Elekta 核磁共振直線加速器，此部分貢獻營收達 4-5 億元。

各事業體營運狀況：

1. **醫管服務與設備銷售：**承業透過租賃方式，將設備置於醫院，並依醫院端的治療次數進行分潤認列營收，如北醫質子治療，目前穩定貢獻承業每月 2-3 千萬元營收，惟近年醫院勞力吃緊，治療量能相對受限下，研究處預估未來醫管服務營收將呈持平至小幅增長狀，考量此，承業未來在設備銷售上將多以賣斷為先，在設備銷售部分，公司除持續引進新高階醫材設備外，Elekta 核磁共振直線加速器目前有幾家大型醫院洽談合作中，預計 2025 年有機會進行 1 台以上營收認列，質子治療系統部分，彰基預計 2H25 取得建築物使用執照後，承業將可進場進行安裝，預計 2027 年將入帳 5000 萬美金外，今年年底前有機會再新增一家合作醫院。
2. **輻照工廠：**3Q24 開始接單，目前以民生用品及食品等高階滅菌訂單為主，汽車、半導體等還在進行相關測試，醫療器材則須待年底取得 ISO 認證及客戶產品檢測後就可進行接單下，研究處認為輻照工廠訂單放量將落於 2Q25，預估 2025 年貢獻營收 3~4 億元，挑戰損益兩平。
3. **富康藥局及其他：**承業持股 49%之富康藥局台灣門市目前約有 40 餘家，每季營收穩定維持在 2-2.2 億元，由於台灣連鎖藥局市場還有拓展空間，預估年底前門市將擴充至 60 家，2025 年因富康藥局營收認列方式將進行調整，即過往僅認列出貨至藥局，2025 年將改至銷售至消費者端才認列，預估將有助提升承業在富康藥局部分營收及利潤認列(淨利率預計可從 1%增至 4-5%)，其他事業體部分，楊梅長照園區(300 床規畫)進行執照申請中，預計明年初動土，最快 2027-28 年完工，寵物醫療部分，除目前一間特種寵物診所外，公司也持續尋找其他合作標的。

財務預估：考量醫管及輻照工廠營運狀況較預期弱，調整 2024 年營收預估由 36.9 億元至 35.7 億元(-7.8%YoY)，毛利率 21.4%(原估 26.1%)，稅後淨利 1.24 億元(-71.2%YoY)，稅後 EPS 0.75 元(原估 1.92 元)，2025 年營收 46.2 億元(原估 49.9 億元)，毛利率 22.8%(原估 28%)，稅後淨利 5.14 億元(+313.4%YoY)，稅後 EPS 3.08 元(原估 3.78 元)。

附表一：當年度損益表

單位：百萬元	24Q1	24Q2	24Q3F	24Q4F	2024F
營業收入	658	958	964	995	3,575
營業毛利	140	196	214	214	764
營業利益	20	64	78	76	239
稅前淨利	14	47	59	57	178
稅後純益	2	28	48	46	124
稅後 EPS (元)	0.01	0.17	0.29	0.28	0.75
營收 QoQ 成長率	-54.74	45.75	0.63	3.22	--
營收 YoY 成長率	-17.83	8.16	30.80	-31.52	-7.79
毛利率	21.25	20.43	22.20	21.51	21.37
營益率	3.09	6.63	8.09	7.64	6.69
稅後純益率	0.21	2.91	4.98	4.62	3.47

資料來源：CMoney；永豐投顧研究處整理 · Oct. 2024

附表二：五個年度損益表

單位：百萬元	2021	2022	2023	2024F	2025F
營業收入	2,440	2,974	3,877	3,575	4,620
%變動率	-4.51	21.92	30.35	-7.79	29.23
營業毛利	849	902	1,068	764	1,053
毛利率 (%)	34.82	30.34	27.55	21.37	22.79
營業淨利	493	476	613	239	518
稅前淨利	491	484	559	178	642
%變動率	5.83	-1.47	15.62	-68.16	260.67
稅後純益	382	357	419	124	513
%變動率	4.16	-6.57	17.47	-70.41	313.71
稅後 EPS * (元)	2.43	2.21	2.55	0.75	3.08
市調 EPS * (元)	2.14	2.54	2.72	1.84	--
PER (x)	18.89	20.77	18.00	59.61	14.90
PBR (x)	1.21	1.21	1.18	1.17	1.20
每股淨值 * (元)	37.79	38.01	38.79	35.69	38.18
每股股利 (元)	2.01	1.97	2.00	2	2
殖利率 (%)	5.98	4.85	3.40	4.36	4.36

* 以目前股本計算


資料來源：CMoney；永豐投顧研究處整理 · Oct. 2024

營運基本資料


同業比較

代號	公司	投資建議	目前股價	市值(億)	稅後 EPS		PE		PB	
					2023	2024	2023	2024	2023	2024


近三年單月營收狀況




近三年單季營收 VS 毛利率趨勢圖




負債比率 VS 存貨周轉天數



歷史 PE 圖



歷史 PB 圖



臺北	永豐證券投資顧問股份有限公司 臺北市忠孝西路一段 80 號 14 樓 電話：(886-2) 2361-0868	永豐金證券股份有限公司 臺北市重慶南路一段 2 號 17 樓 電話：(886-2) 2311-4345
香港	永豐金證券(亞洲)有限公司 香港銅鑼灣新寧道 1 號 7 樓 電話：(852) 2586-8288	
上海	永豐金證券(亞洲)有限公司上海代表處 中國上海市浦東新區世紀大道 1528 號陸家嘴基金大廈 1903A-2 室 電話：(86-21) 6228-8220	

責任聲明

本報告內容僅供參考，客戶應審慎考量本身之需求與投資風險，本公司恕不負任何法律責任，亦不作任何保證。本報告中之內容或有取材於本公司認可之來源，但並不保證其真實性或完整性；報告中所有資訊或預估，變更時本公司將不作預告，若資料內容有未盡完善之處，恕不負責。此外，非經本公司同意，不得將本報告加以複製或轉載。

110 年金管投顧新字第 024 號

SinoPac 投資評等

B：Buy 買進：未來 12 個月該股票表現將優於大盤

N：Neutral 中立：未來 12 個月該股票表現將與大盤一致

S：Sell 賣出：未來 12 個月該股票表現將落後大盤

Analyst Certification:

For each company mentioned in this research report, the respective analyst(s) who cover the company certifies (certify) that all of the views expressed in this research report accurately reflect his (their) personal views about any and all of the subject issuer(s) or securities. The analyst(s) also certifies (certify) that no part of her (their) compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

SinoPac Research Stock Rating System:

Buy: We think the stock will outperform the broader market over the next 12 months.

Neutral: We think the stock will perform in line with the broader market over the next 12 months.

Sell: We think the stock will underperform the market over the next 12 months.

Global Disclaimer:**Important Disclosures for U.S. Persons**

This research report was prepared by SinoPac Securities Corporation (SinoPac), a company authorized to engage in securities activities in Taiwan. SinoPac is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution to "major U.S. institutional investors" in reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act").

Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based on the information provided in this research report should do so only through Auerbach Grayson & Company, 20 Wall West 55th Street, New York, NY 10019, a registered broker dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sell securities or related financial instruments through SinoPac. Auerbach Grayson & Company accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it is delivered to a U.S. person other than a major U.S. institutional investor.

The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA") and may not be an associated person of Auerbach Grayson & Company and, therefore, may not be subject to applicable restrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a research analyst account.

Ownership and Material Conflicts of Interest

Auerbach Grayson & Company or its affiliates does not 'beneficially own,' as determined in accordance with Section 13(d) of the Exchange Act, 1% or more of any of the equity securities mentioned in the report. Auerbach Grayson & Company, its affiliates and/or their respective officers, directors or employees may have interests, or long or short positions, and may at any time make purchases or sales as a principal or agent of the securities referred to herein. Auerbach Grayson & Company is not aware of any material conflict of interest as of the date of this publication.

Compensation and Investment Banking Activities

Auerbach Grayson & Company or any affiliate has not managed or co-managed a public offering of securities for the subject company in the past 12 months, nor received compensation for investment banking services from the subject company in the past 12 months, neither does it or any affiliate expect to receive, or intends to seek compensation for investment banking services from the subject company in the next 3 months.

Additional Disclosures

This research report is for distribution only under such circumstances as may be permitted by applicable law. This research report has no regard to the specific investment objectives, financial situation or particular needs of any specific recipient, even if sent only to a single recipient. This research report is not guaranteed to be a complete statement or summary of any securities, markets, reports or developments referred to in this research report. Neither SinoPac nor any of its directors, officers, employees or agents shall have any liability, however arising, for any error, inaccuracy or incompleteness of fact or opinion in this research report or lack of care in this research report's preparation or publication, or any losses or damages which may arise from the use of this research report.

SinoPac may rely on information barriers, such as "Chinese Walls" to control the flow of information within the areas, units, divisions, groups, or affiliates of SinoPac.

Investing in any non-U.S. securities or related financial instruments (including ADRs) discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on such non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in effect within the United States.

The value of any investment or income from any securities or related financial instruments discussed in this research report denominated in a currency other than U.S. dollars is subject to exchange rate fluctuations that may have a positive or adverse effect on the value of or income from such securities or related financial instruments.

Past performance is not necessarily a guide to future performance and no representation or warranty, express or implied, is made by SinoPac with respect to future performance. Income from investments may fluctuate. The price or value of the investments to which this research report relates, either directly or indirectly, may fall or rise against the interest of investors. Any recommendation or opinion contained in this research report may become outdated as a consequence of changes in the environment in which the issuer of the securities under analysis operates, in addition to changes in the estimates and forecasts, assumptions and valuation methodology used herein.

No part of the content of this research report may be copied, forwarded or duplicated in any form or by any means without the prior consent of SinoPac and SinoPac accepts no liability whatsoever for the actions of third parties in this respect.